Sugi Predict

Sugi Predict / Compounds / SCHEMBL30923945

SCHEMBL30923945

SCHEMBL30923945

O=C(Nc1noc2cc(Cl)cc(-c3c(F)cccc3F)c12)OCC(Cl)(Cl)Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 6/20 0.38
▸ SCN5A Q14524 4/20 0.36
▸ KIT P10721 3/20 0.36
▸ KDR P35968 3/20 0.36
▸ FLT3 P36888 3/20 0.36
▸ TP53 P04637 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MET P08581 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923949 0.92 SCN9A (0.36) SCN9ASCN5AKITKDRFLT3
SCHEMBL30924011 0.90 SCN9A (0.38) SCN9ASCN5ATP53SMN1; SMN2MAPT
SCHEMBL30923979 0.89 TP53 (0.40) SCN9ASCN5AKITKDRFLT3
SCHEMBL30923944 0.85 TP53 (0.38) SCN9ASCN5AKITKDRFLT3
SCHEMBL30923971 0.85 HPGD (0.30) HPGD
SCHEMBL30923936 0.84 KIT (0.38) KITKDRFLT3TP53SMN1; SMN2
SCHEMBL30924013 0.80 THRB (0.32) SCN9ATP53SMN1; SMN2MAPTALOX15
SCHEMBL30923989 0.76 — —
SCHEMBL27219768 0.73 THRB (0.36) TP53MAPTLMNA
SCHEMBL27219926 0.71 KIT (0.33) KITKDRFLT3SMN1; SMN2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-27 — — US disclosed
EP-4612145-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-09-10 — — EP disclosed
US-20240317765-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-09-26 — — US disclosed
US-20240174677-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-30 — — US disclosed
WO-2024095133-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317765-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R SCN9A 688/4885SCN5A 398/4885KIT 1791/4885
US-20240174677-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R SCN9A 688/4885SCN5A 398/4885KIT 1791/4885
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof HCRTR2, HCRTR1, NPY1R SCN9A 710/4885SCN5A 388/4885KIT 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.